Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$140.58
+6.0%		$92.37
$41.50
▼
$166.48
$6.28B2.831.62 million shs773,590 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$14.62
+9.8%		$9.25
$1.76
▼
$15.30
$6.62B0.7619.43 million shs16.97 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$90.78
+1.3%		$103.95
$74.50
▼
$122.20
$6.22B2.01805,712 shs1.41 million shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$24.74
+3.3%		$29.43
$20.32
▼
$40.22
$1.60B1.261.01 million shs918,952 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
0.00%-1.87%+81.25%+95.25%+93.13%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%+2.81%+79.61%+245.63%+544.05%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%-2.21%-11.17%-16.25%-9.43%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
0.00%-3.43%-15.68%-21.16%-18.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$140.58
+6.0%		$92.37
$41.50
▼
$166.48
$6.28B2.831.62 million shs773,590 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$14.62
+9.8%		$9.25
$1.76
▼
$15.30
$6.62B0.7619.43 million shs16.97 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$90.78
+1.3%		$103.95
$74.50
▼
$122.20
$6.22B2.01805,712 shs1.41 million shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$24.74
+3.3%		$29.43
$20.32
▼
$40.22
$1.60B1.261.01 million shs918,952 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
0.00%-1.87%+81.25%+95.25%+93.13%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%+2.81%+79.61%+245.63%+544.05%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%-2.21%-11.17%-16.25%-9.43%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
0.00%-3.43%-15.68%-21.16%-18.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$102.70-26.95% Downside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.62
Moderate Buy$12.90-11.76% Downside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.76
Moderate Buy$140.8955.20% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
2.82
Moderate Buy$44.2578.86% Upside

Current Analyst Ratings Breakdown

Latest STOK, IOVA, GRAL, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$155.00 ➝ $159.00
10/8/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$6.00 ➝ $11.00
10/2/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$105.00 ➝ $175.00
10/1/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $155.00
9/30/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$14.00 ➝ $18.00
9/29/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/29/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$9.00 ➝ $20.00
9/28/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $150.00
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$65.00 ➝ $100.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$15.00
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M42.67N/AN/A$66.13 per share2.13
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$263.50M25.13N/AN/A$1.76 per share8.31
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M32.78N/AN/A$2.08 per share43.64
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$184.42M8.66N/AN/A$6.17 per share4.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.73N/AN/AN/A-89.11%-40.51%-31.65%11/5/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.11N/AN/AN/A-85.59%-159.87%-44.00%11/3/2026 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$6.89M-$3.34N/AN/AN/A-753.60%-59.36%-51.46%11/3/2026 (Estimated)

Latest STOK, IOVA, GRAL, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.0861N/AN/AN/A$114.44 millionN/A
11/3/2026Q3 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.7146N/AN/AN/A$85.53 millionN/A
11/3/2026Q3 2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.9291N/AN/AN/A$8.21 millionN/A
8/6/2026Q2 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.1335-$0.11+$0.0235-$0.11$87.83 million$99.31 million
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
8/4/2026Q2 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.8072-$0.73+$0.0772-$0.73$67.66 million$71.26 million
8/3/2026Q2 2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.7950-$0.93-$0.1350-$0.93$4.89 million$9.33 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.34
3.82
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.45
3.20
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
7.69
7.69

Institutional Ownership

CompanyInstitutional Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
7.80%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
975452.97 million417.64 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41468.53 million64.49 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
17064.53 million58.33 millionOptionable

Recent News About These Companies

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
October 10 at 1:07 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-alignment-zorevunersen-endpoints-could-230942770.html
Stoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual Meeting
October 6, 2026  |  marketscreener.comM
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-announces-presentations-stk-120000821.html
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.9% - What's Next?
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-stoke-therapeutics-nasdaq-stok-shares-down-59-whats-next-2026-10-06/
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
October 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001196435/en/stoke-therapeutics-announces-presentations-of-stk-002-an-investigational-medicine-for-the-treatment-of-autosomal-dominant-optic-atrophy-adoa-at-the-american-academy-of-ophthalmology-aao-2026-annual-meeting/
Stoke Therapeutics, Inc. Announces Completion Of Successful Meeting With The FDA To Align On Planned U.S. NDA For Zorevunersen
October 5, 2026  |  marketscreener.comM
Stoke Therapeutics stock heads into November 3 results below key averages
October 5, 2026  |  ad-hoc-news.deA
Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-completes-fda-meeting-121300798.html
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of ...
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-announces-completion-successful-110000858.html
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 627 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083021
Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,051 Shares of Company Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083003
Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 627 Shares of Stock
October 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-stok-insider-buying-and-selling-2026-10-03/
Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-stoke-therapeutics-nasdaq-stok-stock-insider-jonathan-allan-sells-627-shares-2026-10-02/
Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-stoke-therapeutics-nasdaq-stok-insider-sells-1051-shares-of-stock-2026-10-02/
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-investment-in-stoke-therapeutics-inc-stok-2026-09-27/
Stoke Therapeutics, Inc. Announces Board Changes
September 23, 2026  |  marketscreener.comM
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...
September 23, 2026  |  marketscreener.comM
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
September 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260923239117/en/stoke-therapeutics-appoints-bo-cumbo-to-its-board-of-directors-enhancing-commercial-expertise-as-the-company-advances-zorevunersen-development-toward-potential-fda-approval-and-commercialization/
Stoke Therapeutics (NASDAQ:STOK) Shares Down 9% - What's Next?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-stoke-therapeutics-nasdaq-stok-shares-down-9-whats-next-2026-09-23/
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-stoke-therapeutics-inc-nasdaq-stok-receives-average-rating-of-moderate-buy-from-analysts-2026-09-23/
Stoke Therapeutics stock holds gains after recent data update
September 19, 2026  |  ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAIL stock logo

GRAIL NASDAQ:GRAL

$140.58 +7.97 (+6.01%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$140.50 -0.08 (-0.06%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$14.62 +1.31 (+9.84%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$14.61 -0.01 (-0.08%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$90.78 +1.14 (+1.27%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$90.80 +0.02 (+0.02%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$24.74 +0.79 (+3.30%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$24.74 0.00 (0.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas